ReviewGene therapy2005
Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects.
Review in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Engineered human Diamond-Blackfan anemia disease model confirms therapeutic effects of clinically applicable lentiviral vector at single-cell resolution.Haematologica · 2023Article
- Review
- Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Expanding the genetic code of the human hematopoietic system.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting.Journal of visualized experiments : JoVE · 2018Article
- Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing.Molecules (Basel, Switzerland) · 2018Review
- The β-globin Replicator greatly enhances the potential of S/MAR based episomal vectors for gene transfer into human haematopoietic progenitor cells.Scientific reports · 2017Article
- Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.Advances in experimental medicine and biology · 2017Review
- Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells.The Journal of biological chemistry · 2016Article
- Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX.Biotechnology letters · 2016Article
- A genome editing primer for the hematologist.Blood · 2016Review
- Review
- Magnet-Bead Based MicroRNA Delivery System to Modify CD133Stem cells international · 2016Article
- RNA-based, transient modulation of gene expression in human haematopoietic stem and progenitor cells.Scientific reports · 2015Article
- Long-term and efficient expression of human β-globin gene in a hematopoietic cell line using a new site-specific integrating non-viral system.Gene therapy · 2015Article
- Characterization of nanoparticle mediated laser transfection by femtosecond laser pulses for applications in molecular medicine.Journal of nanobiotechnology · 2015Article
- Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector.PloS one · 2014Article
- Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice.Molecular therapy. Nucleic acids · 2013Article
- Gene therapy for hemoglobinopathies: progress and challenges.Translational research : the journal of laboratory and clinical medicine · 2013Review
- Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serious unwanted complications provoked by retroviral gene transfer into hematopoietic stem cells (HSCs) have recently raised the need for the development and assessment of alternative gene transfer vectors. Within this context, nonviral gene transfer systems are attracting increasing interest. Their main advantages include low cost, ease of handling and large-scale production, large packaging capacity and, most importantly, biosafety. While nonviral gene transfer into HSCs has been restricted in the past by poor transfection efficiency and transient maintenance, in recent years, biotechnological developments are converting nonviral transfer into a realistic approach for genetic modification of cells of hematopoietic origin. Herein we provide an overview of past accomplishments in the field of nonviral gene transfer into hematopoietic progenitor/stem cells and we point at future challenges. We argue that episomally maintained self-replicating vectors combined with physical methods of delivery show the greatest promise among nonviral gene transfer strategies for the treatment of disorders of the hematopoietic system.
Indexed as
Identifiers
16231044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.